Troy Niguidula, MD
Geriatric Medicine · National City, CANPI 1215948849
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$483
- Novartis$239
- Novo Nordisk$237
- AstraZeneca$237
- GSK$207
- AbbVie$193
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,602100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 25 | $483 |
| Novartis | 13 | $239 |
| Novo Nordisk | 16 | $237 |
| AstraZeneca | 12 | $237 |
| GSK | 9 | $207 |
| AbbVie(2 entities) | 9 | $193 |
| Bayer | 8 | $183 |
| Sunovion Pharmaceuticals Inc. | 27 | $180 |
| Heartflow, Inc. | 1 | $175 |
| Pfizer | 7 | $147 |
| Johnson & Johnson | 6 | $110 |
| Boehringer Ingelheim | 4 | $100 |
| Boston Scientific | 2 | $85 |
| Merck | 4 | $78 |
| Mylan Specialty L.p. | 4 | $74 |
| Amarin Pharma, Inc. | 4 | $74 |
| Xeris Pharmaceuticals, Inc. | 4 | $71 |
| Astellas Pharma US Inc | 3 | $69 |
| Dexcom, Inc. | 3 | $67 |
| Ultragenyx Pharmaceutical Inc. | 3 | $66 |
| Edwards Lifesciences | 1 | $54 |
| Abbott | 2 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Mannkind Corporation | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Amgen | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Travere Therapeutics, Inc. | 1 | $23 |
| Neotract Inc. | 1 | $22 |
| Curonix LLC | 1 | $22 |
| Biogen | 1 | $21 |
| Medtronic | 1 | $21 |
| Chiesi USA, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$175
How this compares
$3,602 in reported general payments places this provider in the 90th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $90,342 |
| JardianceEmpagliflozin | 43 | $57,341 |
| JanuviaSitagliptin Phosphate | 50 | $55,441 |
| OzempicSemaglutide | 43 | $43,378 |
| TradjentaLinagliptin | 42 | $39,771 |
| RybelsusSemaglutide | 24 | $25,327 |
| LinzessLinaclotide | 33 | $20,638 |
| EntrestoSacubitril/Valsartan | 23 | $20,133 |
| TrulicityDulaglutide | 16 | $18,234 |
| FarxigaDapagliflozin Propanediol | 11 | $17,835 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $11,470 |
| RetacritEpoetin Alfa-Epbx | 11 | $7,945 |
| MyrbetriqMirabegron | 17 | $7,892 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $6,548 |
| Atorvastatin Calcium | 441 | $4,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $100 | $103,66196 claims |
| PfizerEliquis, Retacrit | $147 | $98,287143 claims |
| Novo NordiskOzempic, Rybelsus | $237 | $68,70567 claims |
| MerckJanuvia | $78 | $55,44150 claims |
| AbbVieLinzess | $193 | $20,63833 claims |
| NovartisEntresto | $239 | $20,13323 claims |
| Lilly USA, LLCTrulicity | $483 | $18,23416 claims |
| AstraZenecaFarxiga | $237 | $17,83511 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $7,89217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in National City
- Ira BravermanNational City$6K
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Vincent HoLancaster$32K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Chaewon SongGarden Grove$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.